FDA

Monte Rosa to Begin Phase I/II Trial of MRT-2359 in MYC-Driven Solid Cancers

Incyte's Pemazyre Nets FDA Approval for Rare Blood Cancer

In Brief This Week: Genprex, Strata Oncology, Bristol Myers Squibb, Turning Point Therapeutics

Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma

Gilead Sciences Files for Trodelvy FDA Approval in HR-Positive Breast Cancer, Buys Rights in Asia

In Brief This Week: AstraZeneca, Merck, Stemline Therapeutics, Caris Life Sciences, Artios Pharma

AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer

Roche Nabs FDA Label Expansion for Ventana CDx Panel

FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer

In Brief This Week: PreludeDx, Lucid Diagnostics, Sumitomo, AnHeart, Salarius, Syros

Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer

Allarity Scraps Dovitinib Single-Agent Plans in Kidney Cancer, Refocuses on Combination Therapies

OriCell Therapeutics Raises $120M in Series B Round

Turning Point Therapeutics Receives Positive FDA Feedback on Repotrectinib NSCLC Application

EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca